Literature DB >> 10894374

The value of a new method for assessing the separate functions of the long tracts and involved segments in patients with cervical myelopathy.

S Hirabayashi1, N Tsuzuki, R Abe, K Saiki, K Takahashi.   

Abstract

In order to assess accurately lesions of the spinal cord in patients with cervical myelopathy we have developed a new method of examination, which is based on the Japanese Orthopaedic Association (JOA) scoring system. The method attempts to assess separately the functions of the long tract and any involved cord segments in respect to the period after treatment. It was used in 117 consecutive patients who were divided into 2 groups based on whether or not there was a T2-high-intensity lesion within the spinal cord, as revealed by a preoperative magnetic resonance imaging scan (MRI). The results of this method correlated well with the MRI findings. It was assumed that the degree of function of the upper limbs in patients with a T2-high-intensity lesion revealed more about a segment than about the long tract.

Entities:  

Mesh:

Year:  2000        PMID: 10894374      PMCID: PMC3620595          DOI: 10.1007/s002640000127

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  3 in total

1.  Clinical outcomes of anterior correction and reconstruction for neurofibromatosis-associated severe cervical kyphotic deformity.

Authors:  Gu Yifei; Shen Xiaolong; Liu Yang; Cao Peng; Yuan Wen
Journal:  Int Orthop       Date:  2018-07-09       Impact factor: 3.075

2.  Cervical myelopathy due to single level prolapsed disc and spondylosis: a comparative study on outcome between two groups.

Authors:  Jong-Seon Ryu; Jong-Woo Chae; Woo-Jin Cho; Han Chang; Myung-Sang Moon; Sung-Soo Kim
Journal:  Int Orthop       Date:  2010-01-29       Impact factor: 3.075

3.  Duration of symptoms in the quantification of upper limb disability and impairment for individuals with mild degenerative cervical myelopathy (DCM).

Authors:  Sukhvinder Kalsi-Ryan; Jerri Clout; Pouya Rostami; Eric M Massicotte; Michael G Fehlings
Journal:  PLoS One       Date:  2019-09-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.